This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

AboutAbout  CRESEMBA®Invasive fungal infections and risk factorsMeet CRESEMBA ®CRESEMBA® patient profilesEfficacyEfficacyInvasive AspergillosisMucormycosis

Menu

Close

LabelDosingDosingDosingSafety ProfileSafety & TolerabilitySafety ProfileEmerging PopulationsEmerging PopulationsICUInvasive fungal infections in the ICUInvasive fungal infections and influenza

Invasive fungal infections in solid organ transplant recipients

Invasive fungal infections and chronic obstructive pulmonary disease

Invasive fungal infections and COVID-19 (CAPA/CAM)
Support & ResourcesResourcesKOL VideosNational/Regional GuidelinesECIL-6 Guidelines
ESCMID
ID Society of America
Videos
Materials
Support & Resources

Information on how to access prescribing information and adverse event reporting can be found towards the bottom of the page.

Which patients can CRESEMBA® help?

CRESEMBA® is an antifungal therapy for invasive aspergillosis, and mucormycosis where amphotericin B is inappropriate.1 Patients who are at risk of invasive aspergillosis or mucormycosis may include those with haematological malignancies, certain underlying conditions, undergoing HSCT, or being treated in the ICU.1–3

Meet Charles

A 65-year-old male with AML currently on consolidation chemotherapy, with moderate renal dysfunction. Charles could be at risk of invasive aspergillosis or mucormycosis.

Download

ButtonLoading
Meet Mark

A 70-year-old male with AML, currently on immunosuppressants and preparing for allogeneic HSCT. Mark could be at risk of invasive aspergillosis or mucormycosis.

Download

Meet Ruth

A 46-year-old female with influenza, currently on antiviral therapy and corticosteroids. Ruth could be at risk of invasive aspergillosis or mucormycosis.

Download

Meet Anika

A 72-year-old female with ARDS, arterial hypertension and moderate renal impairment. Anika could be at risk of invasive aspergillosis or mucormycosis.

Download

Meet Sanjay

A 76-year-old male with COVID-19, currently on corticosteroids. Sanjay could be at risk of invasive aspergillosis or mucormycosis.

CRESEMBA® is not indicated for the treatment of COVID-19

Download

Meet Steve

A 66-year-old male with CLL, currently receiving ibrutinib treatment. Steve could be at risk of invasive aspergillosis or mucormycosis.

Download

How can CRESEMBA® help your invasive aspergillosis patients? Find out more Loading How can CRESEMBA® help your mucormycosis patients, for whom amphotericin B is inappropriate?  Learn more Loading

AML, acute myeloid leukaemia; ARDS, acute respiratory distress syndrome; CLL, chronic lymphocytic leukaemia; COVID-19, coronavirus disease 2019; HSCT, haematopoietic stem cell transplantation.

Prescribing Information:

Click here for CRESEMBA® (isavuconazole) prescribing information

References:

CRESEMBA GB Summary of Product Characteristics.Dagher H et al. IDSA 2020. Poster presentation.Tissot F et al. Haematologica 2017;102(3):433–444.
AboutDownload all CRESEMBA® patient profiles here Download LoadingIt's time to shape the future of antifungal stewardship Take action now Loading
PP-CRB-GBR-1778. March 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​